NCT07469462 The Effects of High-dose Vitamin B6 on Depression and Anxiety Symptoms
| NCT ID | NCT07469462 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Reading |
| Condition | Neural Inhibition |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2026-05-01 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial investigates the effects of Vitamin B6 supplementation on neural inhibition using electroencephalography (EEG), in relation to depression and anxiety symptoms in participants from the general population with a relatively high level of symptoms at baseline. Researchers will compare a placebo group to high-dose Vitamin B6 to test the hypothesis that Vitamin B6 moves the excitation/inhibition balance towards inhibition.
Eligibility Criteria
Inclusion Criteria: * Over 18 years of age and under 41 * Mild to moderate anxiety and/or depression * Normal or corrected to normal vision Exclusion Criteria: * not taking daily dietary supplement containing \>2 mg Vitamin B6 * not taking medication that is a GABA agaonist (our team will check this with you) * not be pregnant * no medical history of epilepsy * no medical history of peripheral neuropathy * not taking the antibiotic Seromycin (prescribed for tuberclosis or urinary tract infection) * no history of brain injury or recent concussion
Contact & Investigator
David T Field
PRINCIPAL INVESTIGATOR
University of Reading
Frequently Asked Questions
Who can join the NCT07469462 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 41 Years, studying Neural Inhibition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07469462 currently recruiting?
Yes, NCT07469462 is actively recruiting participants. Contact the research team at a.cameron@pgr.reading.ac.uk for enrollment information.
Where is the NCT07469462 trial being conducted?
This trial is being conducted at Reading, United Kingdom.
Who is sponsoring the NCT07469462 clinical trial?
NCT07469462 is sponsored by University of Reading. The principal investigator is David T Field at University of Reading. The trial plans to enroll 44 participants.